221 related articles for article (PubMed ID: 38441600)
1. Periostin's role in uterine leiomyoma development: a mini-review on the potential periostin poses as a pharmacological intervention for uterine leiomyoma.
Kiesler ZG; Hunter MI; Balboula AZ; Patterson AL
Arch Gynecol Obstet; 2024 May; 309(5):1825-1831. PubMed ID: 38441600
[TBL] [Abstract][Full Text] [Related]
2. The management of uterine leiomyomas.
Vilos GA; Allaire C; Laberge PY; Leyland N;
J Obstet Gynaecol Can; 2015 Feb; 37(2):157-178. PubMed ID: 25767949
[TBL] [Abstract][Full Text] [Related]
3. The management of uterine leiomyomas.
Lefebvre G; Vilos G; Allaire C; Jeffrey J; Arneja J; Birch C; Fortier M; Wagner MS;
J Obstet Gynaecol Can; 2003 May; 25(5):396-418; quiz 419-22. PubMed ID: 12738981
[TBL] [Abstract][Full Text] [Related]
4. The Effects of Periostin Expression on Fibroid-Like Transition of Myometrial Cells.
Lenis YY; George JW; Lind S; Balboula A; Teixeira JM; Patterson AL
Reprod Sci; 2023 May; 30(5):1616-1624. PubMed ID: 36418534
[TBL] [Abstract][Full Text] [Related]
5. Uterine fibroid management: from the present to the future.
Donnez J; Dolmans MM
Hum Reprod Update; 2016 Nov; 22(6):665-686. PubMed ID: 27466209
[TBL] [Abstract][Full Text] [Related]
6. The management of uterine fibroids in women with otherwise unexplained infertility.
Carranza-Mamane B; Havelock J; Hemmings R; ;
J Obstet Gynaecol Can; 2015 Mar; 37(3):277-285. PubMed ID: 26001875
[TBL] [Abstract][Full Text] [Related]
7. Epidemiological and genetic clues for molecular mechanisms involved in uterine leiomyoma development and growth.
Commandeur AE; Styer AK; Teixeira JM
Hum Reprod Update; 2015; 21(5):593-615. PubMed ID: 26141720
[TBL] [Abstract][Full Text] [Related]
8. Novel therapeutic strategies for leiomyomas: targeting growth factors and their receptors.
Nowak RA
Environ Health Perspect; 2000 Oct; 108 Suppl 5():849-53. PubMed ID: 11035994
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic management of uterine fibroid tumors: updated French guidelines.
Marret H; Fritel X; Ouldamer L; Bendifallah S; Brun JL; De Jesus I; Derrien J; Giraudet G; Kahn V; Koskas M; Legendre G; Lucot JP; Niro J; Panel P; Pelage JP; Fernandez H;
Eur J Obstet Gynecol Reprod Biol; 2012 Dec; 165(2):156-64. PubMed ID: 22939241
[TBL] [Abstract][Full Text] [Related]
10. Review of myomectomy.
Horng HC; Wen KC; Su WH; Chen CS; Wang PH
Taiwan J Obstet Gynecol; 2012 Mar; 51(1):7-11. PubMed ID: 22482961
[TBL] [Abstract][Full Text] [Related]
11. Epigenomic and enhancer dysregulation in uterine leiomyomas.
Mlodawska OW; Saini P; Parker JB; Wei JJ; Bulun SE; Simon MA; Chakravarti D
Hum Reprod Update; 2022 Jun; 28(4):518-547. PubMed ID: 35199155
[TBL] [Abstract][Full Text] [Related]
12. Pre-operative GnRH analogue therapy before hysterectomy or myomectomy for uterine fibroids.
Lethaby A; Vollenhoven B; Sowter M
Cochrane Database Syst Rev; 2001; (2):CD000547. PubMed ID: 11405968
[TBL] [Abstract][Full Text] [Related]
13. The assessment of the relationship between the vascularity of FIGO Type 4-7 leiomyomas and abnormal uterine bleeding.
Gursoy AY; Cakmak D; Akgul G; Kiseli M; Umudum H; Pabuccu R; Caglar GS
J Obstet Gynaecol; 2022 Jan; 42(1):153-157. PubMed ID: 33938365
[TBL] [Abstract][Full Text] [Related]
14. Pre-operative GnRH analogue therapy before hysterectomy or myomectomy for uterine fibroids.
Lethaby A; Vollenhoven B; Sowter M
Cochrane Database Syst Rev; 2000; (2):CD000547. PubMed ID: 10796723
[TBL] [Abstract][Full Text] [Related]
15. Extracellular matrix in uterine leiomyoma pathogenesis: a potential target for future therapeutics.
Islam MS; Ciavattini A; Petraglia F; Castellucci M; Ciarmela P
Hum Reprod Update; 2018 Jan; 24(1):59-85. PubMed ID: 29186429
[TBL] [Abstract][Full Text] [Related]
16. EMAS position statement: management of uterine fibroids.
Pérez-López FR; Ornat L; Ceausu I; Depypere H; Erel CT; Lambrinoudaki I; Schenck-Gustafsson K; Simoncini T; Tremollieres F; Rees M;
Maturitas; 2014 Sep; 79(1):106-16. PubMed ID: 24975954
[TBL] [Abstract][Full Text] [Related]
17. Association Between Patient Characteristics and Treatment Procedure Among Patients With Uterine Leiomyomas.
Borah BJ; Laughlin-Tommaso SK; Myers ER; Yao X; Stewart EA
Obstet Gynecol; 2016 Jan; 127(1):67-77. PubMed ID: 26646122
[TBL] [Abstract][Full Text] [Related]
18. Sphingosine 1-phosphate signaling in uterine fibroids: implication in activin A pro-fibrotic effect.
Bernacchioni C; Ciarmela P; Vannuzzi V; Greco S; Vannuccini S; Malentacchi F; Pellegrino P; Capezzuoli T; Sorbi F; Cencetti F; Bruni P; Donati C; Petraglia F
Fertil Steril; 2021 Jun; 115(6):1576-1585. PubMed ID: 33500141
[TBL] [Abstract][Full Text] [Related]
19. Possible involvement of inflammatory/reparative processes in the development of uterine fibroids.
Protic O; Toti P; Islam MS; Occhini R; Giannubilo SR; Catherino WH; Cinti S; Petraglia F; Ciavattini A; Castellucci M; Hinz B; Ciarmela P
Cell Tissue Res; 2016 May; 364(2):415-27. PubMed ID: 26613601
[TBL] [Abstract][Full Text] [Related]
20. Adipocyte and Adipokines Promote a Uterine Leiomyoma Friendly Microenvironment.
Afrin S; Ramaiyer M; Begum UAM; Borahay MA
Nutrients; 2023 Jan; 15(3):. PubMed ID: 36771423
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
